{"id":393799,"date":"2020-12-04T19:03:24","date_gmt":"2020-12-05T00:03:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=393799"},"modified":"2020-12-04T19:03:24","modified_gmt":"2020-12-05T00:03:24","slug":"cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/","title":{"rendered":"Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting<\/b><\/p>\n<p>CONCORD, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: \u201cEfficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study,\u201d presented by Dr. Nina Khanna of the University Hospital of Basel, Switzerland, at the American Society of Hematology Annual Meeting, on Saturday, December 5, 2020, at 2:45 pm\/EST. This presentation reviews data on the efficacy of INTERCEPT-treated COVID-19 convalescent plasma (CCP) to treat COVID-19 pneumonia patients.\n<\/p>\n<p>\nInitiated in March 2020, the study was conducted in collaboration with Cerus and Vitalant Research Institute, San Francisco; Vaccine Research and Development Laboratory, University of California, Irvine, CA; and Enable Biosciences, San Francisco, CA.\n<\/p>\n<p>\nThe study of hospitalized patients with documented COVID-19 pneumonia enrolled 15 subjects who received INTERCEPT-treated CCP and 30 matched controls who received standard therapy without CCP transfusion. Of the 15 patients treated with INTERCEPT-treated CCP, 14 (93.3%) responded and were alive at study day 28. Three patients were severely immune-compromised. Among the 30 matched control patients, 6 (20%) died by study day 28.\n<\/p>\n<p>\n\u201cThe study summarizes the successful collaboration with the University Hospital of Basel, Cerus, and the other California-based research teams, generating important data to define CCP virus-neutralizing efficacy at the onset of the COVID-19 pandemic. We are encouraged by the patients\u2019 responses to INTERCEPT-treated CCP and the preservation of neutralizing antibodies in INTERCEPT-treated CCP. The data from this study demonstrate the ability to identify effective CCP during epidemics that, with pathogen reduction to decrease the risk of transfusion-transmitted disease, can be rapidly introduced into routine practice,\u201d said Dr. Laurence Corash, Cerus\u2019 chief scientific officer.\n<\/p>\n<p>\nTo view the oral presentation on Saturday, December 5, click here: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fash.confex.com%2Fash%2F2020%2Fwebprogram%2FPaper136180.html&amp;esheet=52343393&amp;newsitemid=20201204005617&amp;lan=en-US&amp;anchor=https%3A%2F%2Fash.confex.com%2Fash%2F2020%2Fwebprogram%2FPaper136180.html&amp;index=1&amp;md5=03ab4f415a0d10f7973f45b04d60ec12\">https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper136180.html<\/a><\/p>\n<p><b>About University Hospital of Basel and the Regional Swiss Red Cross Blood Transfusion Center, Basel, Switzerland.<\/b><\/p>\n<p>\nThe University Hospital of Basel is a specialized medical research and patient care facility. The Regional Swiss Red Cross Blood Transfusion Center, located in the University Hospital, conducts research studies in transfusion medicine.\n<\/p>\n<p><b>About Cerus<\/b><\/p>\n<p>\nCerus Corporation is dedicated solely to safeguarding the world\u2019s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding associated with fibrinogen deficiency, including massive hemorrhage. For more information about Cerus, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cerus.com%2F&amp;esheet=52343393&amp;newsitemid=20201204005617&amp;lan=en-US&amp;anchor=www.cerus.com&amp;index=2&amp;md5=b53307ea5ee896e40f8c878701c4519c\">www.cerus.com<\/a> and follow us on LinkedIn.\n<\/p>\n<p>\nINTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201204005617r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201204005617\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201204005617\/en\/<\/a><\/span><\/p>\n<p>\nJessica Hanover \u2013 VP, Corporate Affairs<br \/>\n<br \/>Cerus Corporation<br \/>\n<br \/>925-288-6137\n<\/p>\n<p><b>KEYWORDS:<\/b> Europe Switzerland United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Medical Supplies Medical Devices Health Infectious Diseases Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201204005617\/en\/724993\/3\/cerus_210x60.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting CONCORD, Calif.&#8211;(BUSINESS WIRE)&#8211; Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: \u201cEfficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study,\u201d presented by Dr. Nina Khanna of the University Hospital of Basel, Switzerland, at the American Society of Hematology Annual Meeting, on Saturday, December 5, 2020, at 2:45 pm\/EST. This presentation reviews data on the efficacy of INTERCEPT-treated COVID-19 convalescent plasma (CCP) to treat COVID-19 pneumonia patients. Initiated in March 2020, the study was conducted in collaboration with Cerus and Vitalant Research Institute, San Francisco; &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-393799","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting CONCORD, Calif.&#8211;(BUSINESS WIRE)&#8211; Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: \u201cEfficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study,\u201d presented by Dr. Nina Khanna of the University Hospital of Basel, Switzerland, at the American Society of Hematology Annual Meeting, on Saturday, December 5, 2020, at 2:45 pm\/EST. This presentation reviews data on the efficacy of INTERCEPT-treated COVID-19 convalescent plasma (CCP) to treat COVID-19 pneumonia patients. Initiated in March 2020, the study was conducted in collaboration with Cerus and Vitalant Research Institute, San Francisco; &hellip; Continue reading &quot;Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-05T00:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201204005617r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting\",\"datePublished\":\"2020-12-05T00:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\\\/\"},\"wordCount\":575,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201204005617r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\\\/\",\"name\":\"Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201204005617r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-05T00:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201204005617r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201204005617r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting - Market Newsdesk","og_description":"Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting CONCORD, Calif.&#8211;(BUSINESS WIRE)&#8211; Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: \u201cEfficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study,\u201d presented by Dr. Nina Khanna of the University Hospital of Basel, Switzerland, at the American Society of Hematology Annual Meeting, on Saturday, December 5, 2020, at 2:45 pm\/EST. This presentation reviews data on the efficacy of INTERCEPT-treated COVID-19 convalescent plasma (CCP) to treat COVID-19 pneumonia patients. Initiated in March 2020, the study was conducted in collaboration with Cerus and Vitalant Research Institute, San Francisco; &hellip; Continue reading \"Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-05T00:03:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201204005617r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting","datePublished":"2020-12-05T00:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/"},"wordCount":575,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201204005617r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/","name":"Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201204005617r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-05T00:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201204005617r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201204005617r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerus-corporation-announces-presentation-of-study-results-with-intercept-treated-covid-19-convalescent-plasma-at-the-american-society-of-hematology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/393799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=393799"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/393799\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=393799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=393799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=393799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}